Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares Purchased by BML Capital Management LLC

by · The Cerbat Gem

BML Capital Management LLC lifted its stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Free Report) by 62.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,186,191 shares of the biotechnology company’s stock after purchasing an additional 837,153 shares during the quarter. Oramed Pharmaceuticals comprises 3.1% of BML Capital Management LLC’s investment portfolio, making the stock its 10th biggest holding. BML Capital Management LLC owned about 5.36% of Oramed Pharmaceuticals worth $5,334,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its position in shares of Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Oramed Pharmaceuticals during the 2nd quarter worth about $40,000. Virtu Financial LLC bought a new position in shares of Oramed Pharmaceuticals during the 1st quarter worth about $68,000. Renaissance Technologies LLC boosted its position in shares of Oramed Pharmaceuticals by 89.0% during the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 108,700 shares in the last quarter. Finally, Murchinson Ltd. boosted its position in shares of Oramed Pharmaceuticals by 23.2% during the 2nd quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock worth $4,369,000 after purchasing an additional 320,495 shares in the last quarter. Institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Trading Down 1.3 %

NASDAQ ORMP traded down $0.03 during trading hours on Tuesday, hitting $2.29. The company’s stock had a trading volume of 85,149 shares, compared to its average volume of 132,016. Oramed Pharmaceuticals Inc. has a 52 week low of $1.87 and a 52 week high of $3.67. The company has a market capitalization of $93.36 million, a PE ratio of 4.55 and a beta of 1.77. The company’s 50-day simple moving average is $2.38 and its two-hundred day simple moving average is $2.38.

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.21. Research analysts anticipate that Oramed Pharmaceuticals Inc. will post 0.24 EPS for the current fiscal year.

Analyst Ratings Changes

ORMP has been the topic of a number of research analyst reports. HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th. StockNews.com cut shares of Oramed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday.

Check Out Our Latest Analysis on Oramed Pharmaceuticals

Oramed Pharmaceuticals Profile

(Free Report)

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.

Further Reading

Want to see what other hedge funds are holding ORMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Free Report).